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Summary 
Type C  retroviruses endogenous to various nonprimate species can infect human cells in vitro, 
yet the transmission of these viruses to humans is restricted. This has been attributed to direct 
binding of the complement component C lq to the viral envelope protein p15E, which leads to 
classical pathway-mediated virolysis in human serum.  Here we report a novel mechanism of 
complement-mediated type C retrovirus inactivation that is initiated by the binding of"natural 
antibody" [Ab] (anti-o~-galactosyl  Ab)  to the  carbohydrate epitope Galod-3Gal[31-4GlcNAc-R. 
expressed on the retroviral envelope. Complement-mediated inactivation of amphotropic re- 
troviral particles was found to be restricted to human and other Old World primate sera, which 
parallels the presence ofanti-0t-galactosyl natural Ab. Blockade or depletion ofanti-o~-galacto- 
syl Ab in human serum prevented inactivation of both amphotropic and ecotropic murine ret- 
roviruses. Similarly, retrovirus was not killed by New World primate serum except in the pres- 
ence of exogenous anti--~-galactosyl Ab. Enzyme-linked immunosorbent assays revealed that 
the cx-galactosyl  epitope was expressed on the surface of amphotropic and ecotropic retrovi- 
ruses,  and Western blot analysis further localized this epitope to the retroviral envelope glyco- 
protein gp70. Finally, down-regulation of this epitope on the surface of murine retroviral par- 
ticle producer cells rendered them, as well as the particles liberated from these cells, resistant to 
inactivation by human serum complement. Our data suggest that anti-~-galactosyl Ab may 
provide a  barrier for the  horizontal transmission  of retrovirus from species  that  express the 
a-galactosyl epitope to humans and to other Old World primates. Further, these data provide a 
mechanism for the generation of complement-resistant retroviral vectors for in vivo gene ther- 
apy applications where exposure to human complement is unavoidable. 
T 
he inactivation of nonprimate-derived type C  retrovi- 
ruses  in  human  serum  has  been  described  as  an 
Ab-independent  mechanism  involving  activation  of the 
classical  complement pathway  through  direct  binding  of 
Clq  to  the  retroviral  surface  protein  p15E  (1-4).  This 
mechanism  of complement  activation  has  also  been  de- 
scribed on the surface of cells coinfected with human T cell 
lymphotropic virus  I  and  III,  although  these  retroviruses 
are not inactivated by human serum (5-7). The serum in- 
activation of type C  retroviruses is primarily restricted to 
Old World primates,  as these viruses survive exposure to 
sera from other mammalian species,  including goat, guinea 
pig,  rabbit,  rat,  and mouse  (1,  5,  8,  9).  Considering that 
nonprimate  type C  retroviruses are  known  to  infect and 
transform human cells in vitro, it has been proposed that a 
species-restricted interaction between human Clq and viral 
pl5E limits  the  transmission  of retroviruses from nonpri- 
mate species to humans (8, 10-13). 
The Galcxl-3Gali31-4GlcNAc-R (cx-galactosyl)  epitope 
is a glycosidic structure that has been identified on the sur- 
face of cells from mammalian species  excluding Old World 
primates  (14,  15).  The  absence  of this  epitope  in  Old 
World  primates  results  from  two  frameshift  mutations 
present  in  the  cil-3galactosyl  transferase  gene  (16-18). 
Cross-reactive c~-galactosyl-like epitopes exist on the sur- 
face of bacteria  constituting the  normal  human  intestinal 
flora as well as certain human pathogens (19).  As much as 
1% of  the total circulating IgG in humans targets this glyco- 
sidic  structure, apparently because of continuous antigenic 
stimulation  from  the  normal  flora  (19-24).  Recent  evi- 
dence suggests  that anti--Ix-galactosyl  natural Ab may pro- 
vide  an  important  immunological  barrier  against  patho- 
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example, the binding of anti--ot-galactosyl  Ab to the surface 
of Trypanosoma  cruzi  has  been  shown  to  induce  comple- 
ment-mediated  lysis  of  this  organism  (25).  In  contrast, 
other studies suggest that binding of anti--a-galactosyl Ab 
to the surface of some bacteria may serve to protect them 
from  complement-mediated damage  by blocking alterna- 
tive complement pathway activation (23, 24). 
In this study, we investigated the role of anti---~-galacto- 
syl natural Ab in the inactivation of type C  retrovirus by 
human  serum  complement.  We show  that  inactivation of 
amphotropic and ecotropic retroviral particles is dependent 
on anti-a-galactosyl Ab and that the ot-galactosyl epitope is 
present on the viral envelope glycoprotein gp70.  Our data 
reveal a novel mechanism of complement-mediated retro- 
virus  killing by  Old World primate  sera  and  suggest  that 
activation  of  complement  by  anti--~x-galactosyl Ab  may 
provide an immunological barrier for the horizontal trans- 
mission  of retroviruses or other enveloped viruses to  hu- 
mans from species that express the ot-galactosyl epitope. 
Materials and Methods 
Retrovirus  TiterAssay.  The  retroviral  vector  pLXSN  (26), 
containing the neomycin resistance gene for selection, was used 
to examine the ability of type C  retrovims to survive in human 
serum. Retroviral particles were generated from the amphotropic 
packaging cell line PA317, which contains the amphotropic mu- 
rine leukemia virus (MLV) 1 gag, pol,  and env genes  (26),  or the 
ecotropic packaging cell line GP+E-86, which contains the eco- 
tropic Moloney murine leukemia virus (MMLV) gag, pol, and ent, 
genes (27). Titers of infectious particles were determined by serial 
dilutions on NIH/3T3 cells. Briefly, 2.5  ￿  104 cells were plated 
per well in six-well plates with 2 ml of DMEM containing 10% 
fetal bovine serum (D10). The medium in each well was replaced 
with 2 ml of D10 containing 8 ~g/ml ofpolybrene, and retrovi- 
ral particles were added. Tenfold dilutions were made from the 
original well, and plates were incubated for 24 h  at 37~  Me- 
dium was  removed, and 2 ~  of D10  containing 500  p~g/ml of 
G418 (active weight) was added. The cells were maintained un- 
der selection for 7 d with two changes of medium during this pe- 
riod.  Finally, medium was removed,  and colonies were stained 
with methylene blue-saturated methanol for 15 rain followed by 
a  brief rinse  in  water.  Wells  containing  <100  colonies  were 
counted to determine titers. 
Retrovirus Killing Assay in Primate Sera.  Retroviral particles from 
PA317,  GP+E-86,  or PA317/H-transferase  cells  (~  CFU) 
were incubated for 30 min at 37~  in 100  I~1 of 40% serum di- 
luted in HBSS and were subsequently titered on NIH/3T3 cells 
to assess retrovirus survival as described above. The different pri- 
mate sera included human (Diamedix Corp., Miami, FL), chim- 
panzee (Southwest Foundation for Research, San Antonio, TX), 
baboon, squirrel monkey, owl monkey, and tarnarin (all from the 
1Abbreviations used in this paper: Gakxl-3Gal, galactose etl-3galactose; GS, 
Griffonia simplicifolia; HRP, horseradish peroxidase; LCMV, lymphocytic 
choriomeningitis virus; MLV, murine leukemia virus; MMLV, Moloney 
murine leukemia virus. 
New  England  Regional  Primate  Research  Center,  Southbor- 
ough, MA). Data were calculated as percent retrovirus survival in 
the various sera relative to the number of input CFU (determined 
by incubation of virus in 40% heat-inactivated human serum). In 
experiments examining the ability to block inactivation of retro- 
viral particles,  human  serum  was  preincubated  with  galactose 
~xl-3galactose (Galal-3Gal; Dextra Laboratories, Reading, UK), 
D(+)  glucose, D(+)  galactose, c~-L(-)  fucose,  maltose, or su- 
crose (all from Sigma Chemical Company, St. Louis, MO) for 30 
rain  at  37~  before the  addition of retrovirus.  In  the  anti-o~- 
galactosyl Ab depletion experiments, retroviral particles were pre- 
incubated with either anti--a-galactosyl Ab (90 Ixg/ml) or buffer 
alone (PBS; BioWhittaker, Inc., Walkersville, MD) for 30 min at 
37~  before the addition of either 40% human serum, 40% hu- 
man  serum  depleted of anti---~-galactosyl  Ab,  or  40%  squirrel 
monkey serum for an additional 30 min incubation. Retrovirus 
survival was then assessed as described above. 
Retrovirus  Purification.  Retroviral particles were isolated from 
the  amphotropic packaging cell line PA317  via centrifugation. 
Briefly, a 24-h supematant was harvested from confluent flasks of 
transduced  PA317  cells.  The  supernatant  was  centrifuged  at 
40,000 g in an SW28 rotor for 90 min. Supernatant was removed, 
and the retroviral pellet was resuspended in HBSS. A 24-h super- 
natant from confluent NIH/3T3  cells was treated similarly as a 
no-virus control for the Western blot analysis. 
Anti-ot-GalactosylAb  Purification.  Anti-a-galactosyl Ab  was 
purified  from  human  serum  using  a  Galod-3Gal-polyacryla- 
mide-glass (B,~-sorbent)  column (Syntesome, Munich, Germany). 
Briefly, 10 ml of human serum was diluted 1:2 in PBS, pH 7.5, 
and passed over a 5-ml Bdi-Sorbent column three times. The final 
column flow through was collected as a source of anti--ot-galactosyl 
Ab-depleted serum. After washing the column extensively with 
PBS, Ab was eluted with immunopure IgG elution buffer (Pierce, 
Rockford, IL) and immediately neutralized by adding 1.0 M Tris, 
pH 8, to a final concentration of 0.1 M. Fractions containing pro- 
tein were combined and dialyzed against PBS overnight. 
ELISA.  Capture  ELISAs  were  performed  using  fiat-bot- 
tomed 96-well microtiter plates. The plates were coated for 1 h 
with Fab generated from an anti-gp70 mAb (purified from MLV 
gp70  hybridoma 715;  National Institutes of Health  AIDS Re- 
search and Reference Reagent Program, Rockxdlle, MD) in 0.1 M 
sodium carbonate buffer,  pH  9.6.  After blocking the  plates in 
Tris-buffered saline (20 mM Tris, pH 7.5,  150 mM NaC1)  con- 
taining  1%  BSA  for  2  h,  either  undiluted  PA317/LXSN  or 
GP+E-86/LXSN viral supematant was added and incubated for 
30 min. In the next step, serially diluted purified anti--~x-galacto- 
syl Ab (starting at 70 Ixg/ml) or biotinylated Griffonia  simplicifolia 
(GS)-IB  4 lectin (starting at 20  Ixg/ml; E.  Y.  Laboratories, Inc., 
San Mateo, CA) was added for a 30-min incubation. Horseradish 
peroxidase  (HRP)-conjugated  streptavidin or  HRP-conjugated 
anti-human  IgG Ab  (Zymed Laboratories, Inc.,  San  Francisco, 
CA) was added for 30 min, and plates were developed using per- 
oxidase substrate. All incubations were performed at 37~  and 
plates were washed between steps with Tris-buffered saline con- 
taining 1% BSA. Absorbance values were measured on a micro- 
plate reader (Bio-Rad Laboratories, Hercules, CA) at 492 nm and 
corrected  for  background  absorbance  using  identically treated 
wells in the absence ofretroviral particles. 
Western Blot Analysis.  Purified  amphotropic  retrovirus  in 
HBSS  or  mock-purified  supematant  was  size  fractionated  via 
SDS-PAGE on a 12% gel. Proteins were transferred to nitrocellu- 
lose, and the membrane was incubated for 1 h in blocking solu- 
tion (500 mM NaC1,  35 mM Tris, pH 7.4, 0.5 mM CaC12, 10% 
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Tween 20). Identical blots were incubated for 45 mm in 5 I~g/ml 
of HRP-conjugated  GS-IB4 lectin,  5  p~g/ml  HRP-conjugated 
Ulex europaeus agglutinin (UEA) lectin (Sigma Chemical Co.), or 
a 1:1,000 dilution ofanti-gp70 mAb (provided by Dr. James Ma- 
son, Alexion Pharmaceuticals, Inc., New Haven, CT), all diluted 
in  fresh blocking solution,  Blots were  washed  twice  with  Ab 
wash solution (500  mM  NaC1,  35  mM  Tris, pH 7.4,  0.5  mM 
CaC12, 0.1% SDS, 1.0% NP-40, and 0.5% deoxycholic acid). The 
blot previously reacted with anti-gp70 mAb was incubated for 20 
min  in  fresh  blocking  solution  containing  1.0%  NP-40  and 
HRP-conjugated  goat  anti-rat  IgG  (1:2,000  dilution)  (Zymed 
Laboratories, Inc.). Finally, blots were washed twice in Ab wash 
solution,  incubated for  1 min  in  enhanced  chemiluminescence 
Western blot reagent, and exposed to enhanced  chemilumines- 
cence Hyperfilm (Amersham Corp., Arlington Heights, IL). 
Generation  and Analysis of H- Transferase/PA317  Trans-duc- 
tants.  The full-length human c~l-2fucosyl transferase  (H-trans- 
ferase)  cDNA was  obtained by PCR  amplification of reverse- 
transcribed cDNA from human epitheliod carcinoma cells using 
primers that flanked the start and stop codons of the molecule. 
The  cDNA  was  subcloned  as  an  EcoR.I  fragment  into  the 
pLXSN retroviral vector. Amphotropic retroviral particles were 
produced through the intermediate ecotropic packaging cell line 
GP+E-86  (27).  Briefly,  GP+E-86  cells  were  transfected with 
pLXSN containing H-transferase or pLXSN alone using the cal- 
cium phosphate method (28)  followed by selection in DI0 me- 
dium containing 500  p~g/rnl  G418.  Transfectants were pooled, 
and a 24-h supernatant was harvested from cells at 90%  conflu- 
ency. The  ecotropic virus stock was used to transduce the am- 
photropic packaging cell line PA317, which was also selected as a 
pool in G418. The transduced PA317 cells were screened for sur- 
face expression of the c~-galactosyl epitope or H-antigen by fluo- 
rescence staining using purified anti--et-galactosyl  Ab, GS-IB4 lec- 
tin, or UEA lectin. Cell-surface staining was performed on 2.5 ￿ 
105 cells with 20 I~g/ml of anti--a-galactosyl  Ab or 10 p~g/ml of 
FITC-conjugated GS-IB4 or FITC-conjugated UEA in 1 ￿  PBS 
with 2% fetal bovine serum. FITC-conjugated goat anti-human 
IgG (Zymed Laboratories, Inc.) was used as a secondary Ab for 
cells incubated with anti--a-galactosyl  Ab. Fluorescence was mea- 
sured by FACS  |  using a FACSort  |  (Becton Dickinson Immuno- 
cytometry Systems, San Jose, CA). 
Complement-mediated Dye Release Assay.  Complement-mediated 
killing  of  PA317  cells  transduced  with  H-transferase  or  the 
pLXSN vector alone was assessed by measuring the release of the 
cytoplasmic indicator dye, Calcein AM (Molecular Probes, Inc., 
Eugene, OR,) after exposure to human serum. PA317 cells were 
grown to confluency in 96-well plates, washed twice with HBSS 
containing 1% BSA, and incubated with 10 p,M Calcein AM at 
37~  for 30 min. Cells were again washed twice before the addi- 
tion of human serum for a 30-min incubation at 37~  Dye re- 
lease was measured on a plate reader (Cytofluor 2350; Millipore 
Corp.,  Bedford,  MA;  excitation,  490  nm;  emission,  530  nm). 
Dye retained, represented as percent cell survival, was calculated 
from the percent dye released relative to total cell-associated dye 
(determined from dye released from cells treated with 1% SDS). 
Dye release from ceils not subjected to serum treatment allowed 
the  determination of background  fluorescence  and  nonspecific 
dye release.  In the  anti--~-galactosyl Ab depletion experiment, 
Calcein AM-loaded cells were incubated for 30 min at 37~  with 
either anti-ot-galactosyl  Ab (90 p~g/ml) or buffer alone (PBS), and 
unbound Ab was removed with two washes in HBSS containing 
1% BSA. Cells were then exposed to either 20% human serum, 
20% anti-a-galactosyl Ab-depleted serum, or 20% squirrel mon- 
key serum for 30 n'fin at 37~  and percent cell survival was de- 
termined as described above. 
Results 
Survival of Retrovirus  in Sera  of Old and New  World Pri- 
mates.  Previous studies have demonstrated that many type 
C  retroviruses are effectively inactivated in Old World pri- 
mate  sera but  not  in  sera from  various  other  mammalian 
species (1, 5, 8, 9). Additionally, recent studies have shown 
that  Old  World,  but  not  New  World,  primates produce 
anti-a-galactosyl Ab (14,  15).  To investigate the potential 
role of this Ab in the inactivation of type C  retroviruses, 
retroviral particles containing the MLV-derived amphotro- 
pic  envelope  were  incubated  in  sera  from  various  Old 
World (human, baboon, and chimpanzee) and New World 
(squirrel monkey, owl monkey, and tamarin) primate spe- 
cies. This retrovirus has been previously shown to be effec- 
tively inactivated in human serum via activation of the clas- 
sical complement pathway in a  manner dependent on the 
formation of the terminal membrane attack complex (C5b- 
9)  (29). All primate sera were shown to have similar func- 
tional  complement  levels in  a  classical pathway-mediated 
chicken erythrocyte hemolytic assay (data not shown). Sera 
from Old World primate species effectively inactivated the 
retrovirus with  a  mean  survival of 7.5%  (Fig.  1).  In con- 
trast,  the  retrovirus  was  resistant  to  inactivation  in  New 
World primate sera with a mean survival of 95%.  The sur- 
vival  of amphotropic  retroviral particles  in  New  World, 
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Figure 1.  Retrovims survival in Old World versus New World primate 
sera. Amphotropic retroviral particles were incubated in sera from Old 
World  primate  species, including  human,  baboon,  or  chimpanzee 
(chimp.), or with sera from New World primate species,  including squirrel 
monkey (sq. monk.), owl monkey (owl monk.), or tamarin. After exposure 
to 40% serum, retrovirus was titered on NIH/3T3 cells to assess  survival 
(see Materials and Methods). Bars represent the percentage of infectious 
particles remaining relative to the  number  of input  virus (determined 
from survival in 40% heat-inactivated human serum). Data represent du- 
plicate determinations of a single experiment, one of three so performed. 
Error bars denote SEM. 
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anti-ot-galactosyl Ab,  suggesting that  this  natural Ab  may 
play a role in complement-mediated inactivation of type C 
retroviruses. 
Galol I-3Gal Blocks Retrovirus  Inactivation  in Human  Serum. 
Synthetic Galotl-3Gal has been shown to  specifically bind 
anti-0t-galactosyl Ab  (19).  Furthermore,  it has  been dem- 
onstrated that this carbohydrate serves as an effective inhib- 
itor  of anti-ot-galactosyl Ab-initiated complement lysis of 
cells  expressing  the  ot-galactosyl  epitope  (30).  To  further 
investigate  the  role  of anti-~-galactosyl Ab  in  retrovirus 
inactivation,  human  serum  was  incubated  with  soluble 
Galcll-3Gal before the addition of retroviral particles. To- 
tal serum complement activity was  unaffected by pretreat- 
ment with the various carbohydrates as assessed in a classical 
complement-mediated  chicken  erythrocyte  hemolytic  assay 
(data  not  shown).  Preincubation  of  human  serum  with 
Gal0tl-3Gal successfully inhibited retrovirus inactivation in 
a  dose-dependent manner (Fig.  2).  The addition of 5  rag/ 
ml  Galcil-3Gal  completely  blocked  complement-medi- 
ated  virolysis.  In  contrast,  D(+)  glucose,  oL-L(--)  fucose, 
maltose,  or sucrose added to  the serum at a  concentration 
of 5 rag/m1 did not affect retrovirus survival. Preincubation 
of serum with D(+)  galactose  (5  mg/ml), which has been 
shown  to  partially  block  anti-oL-galactosyl  Ab  reactivity 
(20,  31,  32),  inhibited  ~25%  of retrovirus  inactivation. 
Similar results were obtained when retroviral particles were 
challenged with serum from other Old World primates, in- 
cluding baboon and chimpanzee  (data not shown).  Taken 
together,  these  data demonstrate that anti-~-galactosyl Ab 
plays  a  major  role  in  the  complement-mediated  inactiva- 
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Figure  2.  Inhibition of retrovirus  inactivation  in human serum  using 
soluble Gal(xl-3Gal. Amphotropic  retroviral particles were  incubated in 
40% human serum in the  presence of soluble carbohydrates, including 
D(+) glucose (glucose), D(+) galactose (galactose), ct-L(-) fucose (fucose), 
Gakxl-3Gal, maltose, or sucrose. After exposure to serum, retrovirus sur- 
vival was assessed (see Fig. 1). The curve represents the percentage of in- 
fectious particles remaining at various concentrations of input Gal0tl-3Gal 
relative to  virus survival in 40% heat-inactivated  human serum.  Single 
points indicate retrovirus survival in the presence of various other carbo- 
hydrates at a concentration of 5 mg/ml. Data represent duplicate determi- 
nations from a single experiment,  one of three so performed. Error bars 
denote SEM. 
tion of murine-derived type C  amphotropic retroviral par- 
ticles in human serum. 
Contribution  of Anti-ee-Galactosyl Ab to Retrovirus Inactiva- 
tion by Human Serum.  Previous  studies  have  described 
type  C  murine  retrovirus  inactivation  by  human  serum 
complement as  an Ab-independent event initiated by the 
direct binding of Clq  to  the  retroviral envelope  (1-4).  In 
the present study, we have demonstrated that complement 
activation on the surface of type C  retroviral particles is ini- 
tiated through an Ab-dependent mechanism involving nat- 
ural Ab directed against the or  epitope. To deter- 
mine  the  direct  contribution  of anti-a-galactosyl  Ab  to 
retrovirus  inactivation,  human  serum  was  selectively  de- 
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Figure  3.  The role  of anti-tx-galactosyl Ab in complement-mediated 
killing of PA317 producer  cells and retrovirus. In A, Calcein AM dye- 
loaded PA317 producer cells were incubated with 20% human serum (hu- 
man), 20% anti-0t-galactosyl Ab-depleted human serum  (w/o anti-gala 
gal), 20% squirrel monkey serum (sq. monk.), or 20% squirrel monkey se- 
rum containing purified  human anti~x-galactosyl Ab  (+  anti-galaga/), 
and dye release was measured. Bars represent percent survival of PA317 
cells calculated as the percent dye retained relative to total cell-associated 
dye. In B, the LXSN amphotropic retroviral particles generated from the 
PA317 producer cells were incubated with the same sera listed above at a 
concentration of 40%, and retrovirus survival was determined (see Fig. 1). 
Bars represent the percentage of infectious particles remaining relative to 
input virus. Data represent duplicate determinations from a single experi- 
ment, one of two so performed. Error bars denote SEM. 
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retroviral particle producer cells or retroviral particles liber- 
ated  from these  cells.  It has been  shown  that  depletion  of 
anti-a-galactosyl natural Ab from human serum eliminates 
the ability of that serum to mediate killing of cells express- 
ing  the  ot-galactosyl  epitope  (32).  After  anti-et-galactosyl 
Ab depletion,  the absorbed serum retained normal levels of 
complement  activity  as  determined  in  a  classical  comple- 
ment-mediated  chicken  erythrocyte  hemolytic  assay  (data 
not  shown).  PA317  cells  producing  LXSN  amphotropic 
retroviral  particles  were  loaded  with  the  cytoplasmic  dye 
Calcein AM and exposed to human serum or anti-~-galac- 
tosyl Ab-depleted  serum.  While  only 30%  of PA317  cells 
survived  exposure  to human  serum,  85% of cells survived 
in the depleted human serum (Fig.  3 A). Similarly,  85% of 
cells  incubated  with  squirrel  monkey  serum,  which  does 
not  contain  anti-ot-galactosyl Ab,  survived,  indicating  that 
anti-et-galactosyl  Ab  had  been  effectively  removed  from 
the depleted human serum. Conversely, addition of the pu- 
rified  anti--~-galactosyl  Ab  to  squirrel  monkey  serum  re- 
sulted in killing of the PA317 cells. These data demonstrate 
that anti-et-galactosyl Ab plays a critical role in the activa- 
tion of complement on the surface ofPA317  retroviral par- 
ticle producer cells. 
To determine  whether  anti-a-galactosyl Ab also plays a 
major  role  in  the  killing  of retroviral  particles  generated 
from  the  PA317  producer  cells,  retrovirus  was  incubated 
with either human serum or anti-ot-galactosyl Ab-depleted 
human serum.  Only 5% of input retrovirus survived in hu- 
man serum, while retrovirus survival in depleted serum was 
100% (Fig. 3 B). As was shown for the PA317 cells, incuba- 
tion  of retroviral  particles  with  untreated  squirrel  monkey 
serum  had  no  effect on  retrovirus  survival,  while  squirrel 
monkey serum in the presence of purified anti-c~-galactosyl 
Ab  effectively inactivated  the  retrovirus.  The  inability  to 
achieve 100% retrovirus inactivation in squirrel monkey se- 
rum could reflect insufficient concentrations  of the anti-ci- 
galactosyl Ab. Although  the final concentration  of purified 
anti-o~-galactosyl Ab  in  the  squirrel  monkey  serum  (r 
Ixg/ml)  was  similar  to  that  previously  reported  in  human 
serum (20), the binding of anti--~-galactosyl Ab to 0~-galac- 
tosyl epitopes associated with  squirrel  monkey serum pro- 
teins may decrease Ab available for binding to the retroviral 
envelope.  Taken together,  these  data indicate  that type  C 
amphotropic  retroviral  particle  inactivation  by human  se- 
rum complement is initiated by anti-tx-galactosyl natural Ab. 
Serum  Survival of Retrovirus  Containing  an Ecotropic  Enve- 
lope.  Previous  studies  have  suggested  that  the  ecotropic 
MMLV  envelope  binds  complement  component  Clq  di- 
rectly,  thus  initiating  complement-mediated  destruction  of 
the  virus in  the  absence  of antibody  (2-4).  In the  present 
study, we have demonstrated that retrovirus containing the 
amphotropic MLV envelope is inactivated in human serum 
primarily through  an  antibody-dependent  mechanism.  To 
determine  if this  mechanism  of retrovirus  inactivation  ex- 
tends to other type C  retroviruses, the role ofanti-oL-galac- 
tosyl  Ab  in  the  inactivation  of retrovirus  containing  the 
MMLV  envelope  (27)  was investigated.  P, etrovirus gener- 
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Figure 4.  Contribution of anti-~-galactosyl natural Ab to the serum in- 
activation of retrovirus containing the MMLV ecotropic envelope. Eco- 
tropic retroviral vector particles were incubated with 40% human serum 
(human), 40% serum containing 5 mg/ml soluble Galod-3Gal (human + 
gala 1-3gal), 40% serum containing 5 mg/ml sucrose (human + sucrose), or 
40%  anti-~-galactosyl  Ab-depleted  human  serum  (human w/o  anti- 
galoegal). After exposure to serum, retrovirus survival was determined (see 
Fig. 1). Bars represent the percentage of infectious particles remaining 
relative to the number of input virus. Data represent duplicate determi- 
nations of a single experiment, one of three so performed. Error bars de- 
note SEM. 
ated  from the  ecotropic  GP+E-86  producer  cell line  was 
exposed  to  serum  in  the  presence  or  absence  of soluble 
GaloL1-3Gal or to serum depleted  of anti--0~-galactosyl Ab. 
As  was  demonstrated  for  the  amphotropic  retrovirus,  the 
MMLV-derived ecotropic retrovirus was inactivated in hu- 
man serum, while virus survival approached 100% with the 
addition of soluble Galod-3Gal (Fig. 4). Similarly, the eco- 
tropic  retrovirus  was  not  effectively  inactivated  in  serum 
depleted  of anti--tx-galactosyl Ab.  The  addition  of sucrose 
to  the  serum  had  no  effect on  survival  of the  retrovirus. 
Taken  together,  these  data  demonstrate  that  the  inactiva- 
tion  of retroviral  vector  particles  containing  two  distinct 
envelopes  is  primarily  mediated  by  the  anti-ot-galactosyl 
natural Ab. 
Expression  of the e~-Galactosyl Epitope  on  the  Viral Enve- 
lope.  We have shown that blockade or removal ofanti-ot- 
galactosyl Ab in human serum prevents inactivation of both 
amphotropic  and  ecotropic  retroviral  vector particles.  To 
confirm  the presence  of the  0t-galactosyl  epitope  on  the 
surface  of the  retroviral  envelope,  a  capture  ELISA  was 
performed.  Plates  were  coated  with  Fab  directed  against 
the  retroviral  envelope  protein  gp70,  and  retroviral parti- 
cles  were  captured  from  supematants  of  amphotropic 
(PA317)  or  ecotropic  (GP+E-86)  producer  cells.  Plates 
were then exposed to affinity-purified anti-a-galactosyl Ab 
or GS-IB  4 lectin.  This lectin has been shown to specifically 
interact with the (i-galactosyl epitope (33, 34). Anti-0t-galac- 
tosyl Ab and GS-IB  4 lectin bound to the amphotropic (Fig. 
5  A)  and  ecotropic  (Fig.  5  B)  retrovirus  in  a  dose-depen- 
dent  manner.  These  data  establish  that  the  ot-galactosyl 
epitope is expressed on the surface of type C  retroviral par- 0.5 
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Figure  5.  Analysis of (x-galactosyl epitope expression on retrovirus by 
ELISA. Amphotropic (A) or ecotropic (B)  supernatants were added to 
plates coated with Fab directed against the gp70 envelope protein and 
were subsequently reacted with either anti--~-galactosyl Ab or biotiny- 
lated IB  4 lectin (amounts indicated on the abscissa). Binding of Ab and lectin 
(indicated on the ordinate) was determined after development in the appro- 
priate HRP-conjugated secondary reagent (see Materials and Methods). 
Absorbance values were corrected for background absorbance using iden- 
tically treated wells in the absence of retroviral particles. Data represent 
duplicate detemlinations from a single experiment, one of two so per- 
formed. Error bars denote SEM. 
ticles  containing  two  distinct  envelopes  and  that  anti-lx- 
galactosyl natural Ab binds directly to this epitope. 
Association  of the a-Galactosyl  Epitope  with  the  Viral gp 70 
Envelope Protein.  A recent study has demonstrated that the 
cl-galactosyl epitope is associated with the envelope glyco- 
proteins E1  and E2 of the eastern equine encephalitis virus 
(34).  We  have  shown  that  the  0t-galactosyl  epitope  is 
present on the surface ofamphotropic and ecotropic retro- 
viral particles.  To detemline  if the (x-galactosyl moiety on 
the retroviral surface is associated with a particular envelope 
protein,  Western  blot analysis was performed.  Protein  ex- 
tracts  from purified  amphotropic  retroviral  particles  were 
assayed for reactivity  with  GS-IB  4 lectin,  UEA lectin,  or 
anti-gp70  mAb.  The  GS-IB4 lectin  specifically recognized 
a molecule at ~70 kD (Fig. 6). This molecular weight cor- 
responds with  that of the MLV major envelope  glycopro- 
tein,  gp70.  The  anti-gp70  mAb recognized a  molecule  at 
the same position on the blot,  indicating that the ci-galac- 
Figure  6.  Western blot analysis of (x-galactosyl epitope expression on 
purified retrovirus. Purified arfiphotropic retroviral particles (lane 1) or 
mock-purified supematant from cells not producing retrovirus (lane 2) 
were subjected to SDS-PAGE  and transferred to nitrocellulose. Individual 
blots were then subjected to Western blot analysis using either anti-gp70 
mAb (A), HRP-conjugated GS-IB  4 lectin (B), or HRP-conjugated UEA 
lectin (C) (see Materials and Methods). Protein size in kilodaltons is indi- 
cated to the left of the figure. 
tosyl  epitope  is  associated  with  gp70.  UEA lectin,  which 
recognizes a  different glycosidic structure  (see below),  did 
not react with gp70 or any other molecule on the blot.  Pu- 
rified supernatants  from NIH/3T3  cells  did not react with 
lectins or the m_Ab, confirming that the 70-kD band was of 
viral origin. These results demonstrate that the oL-galactosyl 
epitope expressed on the surface ofretroviral particles is as- 
sociated with the envelope glycoprotein gp70. 
Down-regulation  of the oe-Galactosyl  Epitope on  PA317  Pro- 
ducer  Cells  Results  in  the  Production  of Serum-resistant  Retro- 
virus.  We  have  recently  shown  that  overexpression  of 
H-transferase in porcine cells (LLC-PK1) drastically reduces 
the  expression  of  the  oe-galactosyl  epitope  because  of 
substrate  competition  between  the  H-transferase  and  cll- 
3galactosyl transferase enzymes (Sandrin, M. S., W. L. Fodor, 
E.  Mouhtouris,  S.  A.  Rollins,  E.  R.  Guilmette,  E.  Setter, 
S. P. Squinto, and I. F. G. McKenzie, manuscript submitted 
for  publication).  Furthermore,  down-regulation  of  the 
ci-galactosyl  epitope  on  these  cells  resulted  in  decreased 
sensitivity  to  human  serum  killing.  The  H-transferase 
enzyme  transfers  a  fucose  residue  to  an  N-acetyl  lactos- 
amine  acceptor  to  generate  fucosylated  N-acetyl  lactos- 
amine (H-antigen),  a glycosidic structure  that is not recog- 
nized  by  anti--ix-galactosyl  Ab  (35).  To  investigate  the 
effect of ci-galactosyl epitope  down-regulation  on  the  se- 
rum sensitivity of retrovirus,  H-transferase was expressed in 
the  PA317  retroviral  particle  producer  cells.  PA317  pro- 
ducer cells  were transduced with H-transferase  (PA317/H- 
transferase)  or  the  pLXSN  vector  alone  (PA317/LXSN) 
and  selected  as  pools  in  G418.  Transduced  cells  were  re- 
acted  with  GS-IB  4 lectin,  UEA  lectin  (which  recognizes 
the  H-antigen),  or  anti-~-galactosyl  Ab  and  analyzed  by 
FACS  |  PA317/LXSN  cells  expressed  high  levels  of the 
(x-galactosyl  epitope,  while  expression  of  H-antigen  m 
1350  Retrovirus Killing by Anti--~-Galactosyl Natural Antibody Ii 
a) 
Z 
A 
control 
UEA 
-t~)  .......  i01  .......  i~  .......  i~  "  "  i~, 
m 
m 
0 
> 
m 
r 
B 
-  control 
:~  "i~ 
t: C 
c on  tr'o  1 
H-trans. 
'i@  ......  i~ 
Log  Fluorescence  Intensity 
Figure 7.  FACS  |  analysis of a-galactosyl epitope expression in PA317/ 
H-transferase transductants. The PA317 amphotropic  packaging cell hne 
was transduced with either H-transferase or the pLXSN vector alone and 
selected with G418. Transduced  cells were  reacted with GS-IB  4 lectin, 
UEA lectin, or anti-et-galactosyl Ab and analyzed by FACS  |  (see Materi- 
als and Methods). UEA lectin staining (UEA) indicates expression levels 
of the H-transferase product (H  antigen), while  GS-IB  4 lectin staining 
(GSolB4) indicates a-galactosyl epitope expression. A and B show lectin 
binding to PA317 cells transduced with the LXSN vector alone or with 
H-transferase, respectively. Unstained cells are indicated  in each panel 
(control). C shows the reactivity of PA317 cells transduced with H-trans- 
ferase (H-trans.) or LXSN vector alone (LXSN) with the purified anti-~- 
galactosyl Ab. H-transferase cells incubated with secondary Ab alone are 
also shown (control). 
these  cells  was  low  (Fig.  7  A).  Conversely,  PA317/H- 
transferase  cells showed  an increase  in  H-antigen expres- 
sion, while e~-galactosyl epitope expression was reduced by 
>90%  (Fig.  7  B).  Similarly,  binding of purified  anti-~- 
galactosyl Ab to the PA317/H-transferase producer cells was 
greatly reduced (Fig. 7  C). These results show that expres- 
sion of H-transferase in the PA317 producer cells drastically 
reduces o~-galactosyl epitope expression. 
In an attempt  to  correlate  (x-galactosyl epitope  expres- 
sion with human serum killing, the sensitivity of both  the 
PA317/H-transferase producer cells and the retroviral par- 
ticles liberated from these  cells was  investigated. The pro- 
ducer  cells were  incubated with  human  serum,  and  their 
survival was assessed in a dye release assay. PA317/H-trans- 
ferase cells showed a marked increase in survival relative to 
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Figure 8.  Serum sensitivity of PA317/H-transferase  producer  cells and 
retrovirus  after a-galactosyl  epitope  down-regulation.  (A)  PA317  cells 
transduced with either H-transferase (PA317~H-trans.)  or the LXSN vec- 
tor alone (PA317/LXSN)  were subjected to a complement-mediated  dye 
release assay (see Materials and Methods).  Curves represent PA317 cell 
survival at increasing concentrations  of human serum  calculated as the 
percent  dye retained relative to total cell-associated dye. (B) R.etroviral 
particles  liberated  from  PA317  cells transduced  with  H-transferase 
(PA317/H-ttans.)  or the LXSN vector alone (PA317/LXSN)  were sub- 
jected to 40% human serum, and retrovirus survival was determined (see 
Fig. 1). Bars represent the percentage  of infectious vector  particles re- 
maining relative to input virus. Data represent duphcate determinations of 
a single experiment, one of two so performed. Error bars denote SEM. 
PA317/LXSN  cells after exposure to human serum (Fig. 8 
A).  These  results  indicate  that  the  level  of (x-galactosyl 
epitope expression inversely correlates with the survival of 
PA317  retroviral particle producer  cells in human  serum. 
Concomitantly,  56%  of  retrovirus  generated  from  the 
PA317/H-transferase  producer  cells  survived  exposure  to 
human  serum,  while  only  1%  of  retrovirus  from  the 
PA317/LXSN  producer  cells  survived  (Fig.  8  B).  These 
data indicate that down-regulation of ot-galactosyl epitope 
expression on producer cells results in the release of retro- 
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rum complement. 
Discussion 
In this study, we show that inactivation of murine type 
C amphotropic and ecotropic retroviral particles by human 
serum complement is initiated by the binding of natural Ab 
to c~-galactosyl  epitopes  on  the  retrovirus envelope. This 
mechanism of inactivation requires that the retrovirus orig- 
inates  from cells  that  encode  a  functional od-3galactosyl 
transferase  (i.e., cells derived from mammalian species other 
than Old World primates).  Consistent with these observa- 
tions are reports in the literature demonstrating that envel- 
oped viruses propagated in cells from various species differ 
in  their sensitivity to  human  serum killing.  For example, 
vesicular stomatitis virus is resistant  to inactivation by hu- 
man  serum  when  propagated  in  human  cells  (Hep-2)  as 
compared with vesicular stomatitis virus passaged  through 
rat, hamster,  or dog cells  (36).  Additionally,  the lympho- 
cytic choriomeningitis virus (LCMV)  is less susceptible to 
inactivation  by  human  serum  when  propagated  through 
human cells (HeLa) in comparison with the same virus lib- 
erated from mouse L cells  (37).  Sera from agammaglobu- 
linemic patients fails to inactivate LCMV grown in mouse 
L cells,  indicating that lysis of this virus is Ab dependent. 
Interestingly, LCMV is resistant to human serum inactiva- 
tion  when  passaged  through  baby  hamster  kidney  cells, 
which have been reported to lack expression of the ot-ga- 
lactosyl epitope (37, 38). More recently, the inactivation of 
various type C  retroviruses in human serum was shown to 
be dependent on both the viral genome and producer cell 
type (39). 
In addition to reports on the decreased sensitivity of vi- 
ruses  to human  serum after passage  through human  cells, 
some  studies  have  shown  that  certain  viruses  passaged 
through human cells remain sensitive to lysis by human se- 
rum (1, 5,  39, 40).  There are several possible explanations 
for  viral  inactivation  in  the  absence  of the  0t-galactosyl 
epitope, including activation of complement by specific an- 
tiviral  Ab  or  Ab-independent  activation  of complement 
through the alternative or classical pathway.  Other studies 
have reported that sera from agammaglobulinemic patients 
were able to lyse retrovirus (8, 37).  However, the possibil- 
ity  that  these  sera  contained  sufficient  concentrations  of 
anti-~-galactosyl Ab to activate complement on the surface 
of the virus cannot be ruled out. For example, it has been 
shown that a patient with Bruton type agammaglobuline- 
mia maintained 20% of the anti-o~-galactosyl Ab reactivity 
when  compared  with  an  age-matched individual  (20).  it 
has also been reported that guinea pig serum added to heat- 
inactivated  human  serum  failed  to  inactivate  retrovirus, 
again suggesting that killing of retrovirus is antibody inde- 
pendent (1).  We  have  demonstrated  that  sensitization  of 
retrovirus  with  purified  anti-o~-galactosyl  Ab  before  the 
addition  of squirrel  monkey  serum  can  induce  comple- 
ment-mediated virolysis. One plausible explanation for this 
discrepancy is that, in the previous experiments, heat-inac- 
tivated human serum was added to guinea pig serum before 
the addition of virus.  Under these conditions the anti--~- 
galactosyl Ab may bind guinea pig serum proteins that ex- 
press  the  cl-galactosyl epitope  and  effectively block  their 
ability to bind to  the  retroviral envelope.  Indeed,  in  the 
present  study,  it was  critical  to  add  the  purified anti--~- 
galactosyl Ab  to  the  virus before the  addition  of squirrel 
monkey serum to achieve effective retrovirus inactivation. 
We have also demonstrated that the addition of heat-inacti- 
vated human serum to the anti-cl-galactosyl Ab-depleted 
serum restores the ability of that serum to inactivate retro- 
virus, again indicating that retroviral killing in human  se- 
rum is an antibody-dependent event (data  not shown).  In 
any case, our results  clearly demonstrate that the ~x-galacto- 
syl epitope on the surface of murine-derived retroviral par- 
ticles plays a critical role in their inactivation in human se- 
rum. 
The  host  range  subgroups  of MLV  include  ecotropic, 
xenotropic, polytropic, and amphotropic, which are deter- 
mined by the recognition of cell-surface receptors by the 
gp70 envelope protein (41).  In the present study, we show 
that  human  serum  inactivation  of retroviral particles  ex- 
pressing the MLV amphotropic envelope (26)  is mediated 
by  anti-ci-galactosyl natural  Ab  and  complement.  These 
retroviral particles were chosen because of their broad host 
range,  including  mouse,  rat,  chicken,  cat,  dog,  monkey, 
and human  cells  (42).  We also  demonstrate that MMLV- 
derived ecotropic retroviral particles (27) express the 0~-galac- 
tosyl epitope and are inactivated in human serum by anti- 
oe-galactosyl  Ab.  Involvement of the oL-galactosyt epitope 
in the human serum sensitivity of other type C retroviruses 
or  of enveloped viruses  in  general  seems  likely.  The 0~- 
galactosyl epitope has been detected on the surface of the 
eastern  equine  encephalitis  virus  and  the  Friend  murine 
leukemia virus (34, 43), although the role of this epitope in 
the  serum  activation of these viruses has  not been  deter- 
mined.  In  addition,  studies  have  demonstrated that  natu- 
rally occurring human  antibodies  that  develop soon  after 
birth recognize umdentified envelope glycoproteins of  several 
type C retroviruses (44-46). These antibodies bind retrovi- 
rus propagated in cells from various species  but fail to rec- 
oguize retrovirus grown in Old World primate cells,  sug- 
gesting that they recognize determinants of cellular rather 
than viral origin. These data are in agreement with the spe- 
cies-restricted expression of the  ci-galactosyl epitope  (14, 
15,  19) and support the potential role of anti-~x-galactosyl 
Ab in restricting the horizontal transmission of type C  ret- 
roviruses to humans. 
In  this  report,  we  demonstrate  that  the  o~-galactosyl 
epitope is associated with the retroviral envelope glycopro- 
tein gp70.  However, our experiments do not rule out the 
possibility that  this  epitope is also  acquired as part  of the 
lipid  bilayer when  the  retrovirus passes through  the  host 
cell membrane.  Indeed,  the  or  glycosidic struc- 
ture has been reported to be expressed on glycosphingolip- 
ids associated with the cell membrane  (22).  In any event, 
our results  indicate  that  the  level of or  epitope 
expression on the surface of the retroviral particles is suffi- 
1352  Retrovirus Killing by Anti--~-Galactosyl  Natural Antibody cient for Ab sensitization leading to inactivation by human 
complement. 
Nonprimate type C  retroviruses have been shown to in- 
duce T  cell neoplasms in rodents (47-49) as well as to in- 
fect and transform human cells in vitro (10-13). However, 
the  pathogenic  potential  of these  retroviruses in  humans 
and other Old World primates is controversial. For exam- 
ple, amphotropic MLV infused into rhesus monkeys is rap- 
idly cleared from the bloodstream and fails to cause disease 
(9). Conversely, stern cells from rhesus monkeys transduced 
ex  vivo  with  MLV  induce  fulminant  lymphomas  when 
transplanted back into the donor (50).  Our findings offer a 
plausible  explanation for these  data in that retrovirus de- 
rived from murine producer cells expressing the cx-galacto- 
syl epitope would be rapidly inactivated in Old World pri- 
mate  sera.  However,  ex  vivo  transduction  of stem  cells 
derived from Old World primates in the absence of serum 
complement would allow the retrovirus to survive and rep- 
licate.  Consequently,  retrovirus liberated from these  cells 
would not express the cr  epitope and would there- 
fore  escape  natural  Ab-mediated  destruction  after  trans- 
plantation back into primates. 
In  addition  to  the  potential importance  of this  natural 
Ab-dependent mechanism of virolysis as an immunological 
barrier, it may also have important implications in the field 
ofgene therapy. The majority of vector systems used today 
in  retroviral-mediated gene  transfer  experiments  are  de- 
rived  from  MLV  (51-53).  Although  these  vectors  have 
provided useful tools for in vitro gene transfer, experiments 
performed in vivo have been primarily restricted to nonpri- 
mate species.  The inactivation of murine-derived retroviral 
particles in human serum represents a formidable barrier for 
many potential applications of in vivo retroviral-mediated 
gene therapy. We have previously reported that pretreat- 
ment  of human  serum  with  functionally blocking  mAbs 
that  target  terminal  complement  components  effectively 
protects retroviral particles from inactivation  (29).  In  the 
present study we  demonstrate that retroviral particles can 
be  protected from complement-mediated inactivation by 
the addition of soluble Gahxl-3Gal. These reagents could 
be valuable for certain applications of in vivo gene therapy 
in humans where exposure to complement is unavoidable. 
Additionally, the generation of retroviral vector packaging 
cell  lines  that  do  not  express  the  cx-galactosyl  epitope 
would allow for the production of retroviral particles that 
survive  complement-mediated inactivation in  human  se- 
rum.  Indeed, our data show that down-regulation of this 
epitope in PA317 producer cells results  in the production 
of retroviral particles that are resistant to human  comple- 
ment. Other potential strategies  include the use of packag- 
ing cell lines derived from Old World primates or certain 
Chinese hamster ovary or baby hamster kidney cell lines, 
all  of which  apparently  do  not  express  the  cx-galactosyl 
epitope (14,  15, 38). 
Previous studies have suggested that complement-medi- 
ated inactivation of murine type C  retroviruses in human 
serum is initiated via direct binding of Clq to the MMLV en- 
velope protein p15E (2-4). Several findings in the present 
study bring into question the relative contribution of this 
Ab-independent mechanism to the inactivation of type C 
retroviruses. These include the following: (a) Type C  am- 
photropic retroviral particles were  inactivated by primate 
sera  that  contain  anti-a-galactosyl  Ab  (Old  World  pri- 
mates) but not by sera from primates that do not produce 
such  Ab  (New World primates);  (b)  addition  of purified 
human anti--a-galactosyl Ab to New World primate serum 
resulted  in  retrovirus inactivation;  (c)  the  inactivation  of 
retroviral particles containing either the amphotropic MLV 
or the  ecotropic MMLV  envelope was  completely abro- 
gated by the selective removal of anti--ec-galactosyl Ab from 
or the addition of soluble Galctl-3Gal to human serum; (d) 
the cx-galactosyl  epitope was  demonstrated on the surface 
of both the amphotropic and ecotropic retroviral envelopes 
in association with the glycoprotein gp70; (e) down-regula- 
tion  of cx-galactosyl  epitope  expression  on  amphotropic 
PA317 retroviral particle producer cells resulted in the pro- 
duction of retrovirus that was  resistant to  inactivation by 
human serum complement. Taken together, these data sug- 
gest that the predominant mechanism of type C  retrovirus 
inactivation in human serum is mediated by anti-a-galac- 
tosyl natural Ab. Furthermore, this study suggests  that this 
Ab provides a barrier to the horizontal transmission of ret- 
roviruses from species that express the c~-galactosyl epitope. 
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